Uploaded byDupontInv
PDF, PPTX2,782 views

DuPont Presents at Jefferies 10th Annual Global Industrials Conference

Douglas Muzyka presented on DuPont's strategy to drive higher growth and value through science. The company focuses on three strategic priorities: extending leadership in agriculture and nutrition, building bio-based industrial businesses, and strengthening its position in advanced materials. DuPont will pursue these priorities through innovation in key markets like food, energy, and protection, applying its integrated science capabilities. The company aims to achieve 7% sales growth and 12% operating EPS growth through these initiatives and operational priorities of innovation, global reach, and execution.

Embed presentation

Download as PDF, PPTX
DuPont: Building Higher Growth, Higher Value Through Science Douglas Muzyka, Ph.D. Senior Vice President; Chief Science & Technology Officer
2 2 Regulation G The attached charts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this data is meaningful to investors because it provides insight with respect to ongoing operating results of the company and allows investors to better evaluate the financial results of the company. These measures should not be viewed as an alternative to GAAP measures of performance. Furthermore, these measures may not be consistent with similar measures provided by other companies. This data should be read in conjunction with previously published company reports on Forms 10-K, 10-Q, and 8-K. These reports, along with reconciliations of non-GAAP measures to GAAP are available on the Investor Center of www.dupont.com under Key Financials & Filings. Forward Looking Statements During the course of this presentation we may make forward-looking statements or provide forward-looking information. All statements that address expectations or projections about the future are forward-looking statements. Some of these statements include words such as “plans,” “expects,” “will,” “anticipates,” "believes," “intends,” and “estimates.” Although they reflect our current expectations, these statements are not guarantees of future performance, but involve a number of risks, uncertainties, and assumptions. Some of which include: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; global economic and capital markets conditions; litigation and environmental matters; changes in laws and regulations or political conditions; business or supply disruptions; ability to protect and enforce the company’s intellectual property rights; successful integration of acquired business and separation of underperforming or non-strategic assets; and successful completion of the proposed spinoff of the Performance Chemicals segment including ability to fully realize the expected benefits of the proposed spinoff. The company does not undertake to update any forward-looking statements as a result of future developments or new information. Developing Markets Total developing markets is comprised of Developing Asia, Developing Europe, Middle East & Africa, and Latin America. A detailed list of all developing countries is available on the Earnings News Release link on the Investor Center website at www.dupont.com.
DuPont is a Science Company We work collaboratively to find sustainable, innovative, market- driven solutions to solve some of the world’s biggest challenges, making lives better, safer, and healthier for people everywhere. © National Geographic image Our Purpose 3
Science is the Growth Engine for the Company *2013 revenue from products introduced in the last four years $ 5.8B* new product revenue $ 0.4B* new product revenue $ 3.9B* new product revenue Ag & Nutrition Bio-Based Industrials Advanced Materials • Seeds • Traits • Crop Protection • Specialty Food Ingredients • Enzymes • Biomaterials • Biofuels • Biochemicals • Electronic Materials • Protective Materials • Alternative Energy • Advanced Polymers • Advanced Processes 4
AG & NUTRITION BIO-BASED INDUSTRIALS ADVANCED MATERIALS Three Strategic Priorities Drive the Value of DuPont… Extend leadership across high-value, science-driven segments of the Ag and food value chain Develop world-leading industrial biotech capabilities to create new businesses Grow leading position in differentiated high- value materials 5 Higher Growth, Higher Value Company Through Three World-Leading Positions
• Rigorous pipeline management • Disciplined project execution • Increasing return on R&D • Driving penetration in fast-growing, developing markets • Delivering ongoing productivity • Optimizing resource allocation • Returning cash to shareholders …Together with Three Key Operational Priorities INNOVATION GLOBAL REACH EXECUTION 6
Delivering Value through Innovation 7
Disciplined Project Management Ensures Alignment Between Science and Integrated Business Innovation Processes Stage 0 Governance & Project Execution Innovation Portfolio Management Ideas & Opportunity Choices Insights Brand Technology Marketing Launch Management 8
Increasing our Return on R&D Key Aspects of Measurement Process • Segmentation of R&D spend into 4 categories • Strict financial rigor behind R&D programs • Calculation of projected returns on top R&D programs • Metrics package & dashboards to assess progress versus commitments R&D Spend Distribution Discovery and Major Growth Sustain and Incremental Growth 9 Disciplined and Rigorous Process to Measure and Improve Return on R&D
10 Exceeded $1 Billion Revenue in 2013 Optimum® AQUAmax® Hybrids Agriculture-Discovery & Major Growth Rynaxypyr® Insecticide 10 Million Acres Expected in 2014 2008-2013: 12% Sales CAGR, Operating Margins +600bps* *Non GAAP Number, See Appendix
11 Solamet® Frontside Silver Pastes Advancing Solar Cell Efficiency DuPont™ OLED Technology Electronics & Communications-Discovery & Major Growth Solamet® Two License Agreements Industry Leading Market Positions, Innovation Fueling Earnings Growth
12 Cellulosic Ethanol Plant Industrial Biosciences-Discovery & Major Growth Cold Water Enzymes 1st Half 2014 Operating Earnings Increased 37%, Operating Margins Increased 440bps* Innovation of the Year** Start up expected late 2014 Nevada, Iowa **2014 Sustainable Bio Award for Bio-Based Product Innovation of the Year*Non GAAP Number, See Appendix
13 Products for children, adults and sports enthusiasts Improved Health Nutrition & Health-Discovery & Major Growth Probiotics Regulatory Achievements & New Capacity 1st Half 2014 Operating Earnings Increased 45%*, Operating Margins Increased 320bps* HOWARU® Protect probiotics *Non GAAP Number, See Appendix
DuPont™ Opteon® YF Refrigerant • Collaborative approach to development • A near drop-in solution to enable regulatory compliance • Expect 2014 sales of $100 million Performance Chemicals- Discovery & Major Growth Science Meeting Market Needs for more Sustainable Solutions 14
15 Five Patents Granted, Two In Progress Surlyn® Ionomer Performance Materials-Sustained and Incremental Growth Zytel® RS Renewable Polymers New Golf Ball Line 2014 Operating Margins of 19%*, Above Long Term Goal of 16-18% *Non GAAP Number, See Appendix
16 Tyvek® ThermaWrap™ DuPont™ Kevlar® Safety & Protection -Sustained and Incremental Growth New Launches 50 Years of Innovation 1st Half 2014 Operating Earnings increased 24%*, Operating Margins increased 330bps* *Non GAAP Number, See Appendix
Putting Science to Work: Where we are Going 17
…COMPELLING MARKET INSIGHTS TO SOLVE WORLD SCALE CHALLENGES WORLD CLASS INTEGRATED SCIENCE COUPLED WITH… Translating Science into Solutions Materials Science Chemistry Biological Sciences Engineering Integration of emerging biological sciences FOOD ENERGY PROTECTION Materials ScienceChemistry Biological SciencesEngineering 18 DuPont is on the Forefront of Another Wave of Innovation
19 7% 12%Sales CAGR Operating EPS CAGR* Ushering in the next era of innovation OPERATIONAL PRIORITIES Innovation Global Reach Execution STRATEGIC PRIORITIES Extended Ag & Nutrition Leadership Build Bio-based Businesses Strengthen Advanced Materials Long Term Growth Targets 19 *Non GAAP Number
E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES NON-GAAP RECONCILIATIONS (UNAUDITED) JUNE 30, 2014 Note : Operating earnings are defined as earnings from continuing operations (GAAP) excluding “significant items” and “non-operating pension and other post-employment benefit (OPEB) costs”. Management believes that an analysis of operating earnings, a "non-GAAP" measure, is meaningful to investors because it provides insight with respect to ongoing operating results of the company. Such measurements are not recognized in accordance with generally accepted accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance. Non-GAAP Reconciliations
E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES Year Year Year Year Year 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11 2008 Agriculture 8,009 3,615 4,394 11,739 1,806 1,633 3,631 4,669 10,426 1,535 1,423 3,388 4,080 9,166 1,297 1,368 2,997 3,504 6,549 Electronics & Communications 1,197 617 580 2,549 642 638 653 616 2,701 622 607 795 677 3,173 630 841 891 811 2,194 Industrial Biosciences 618 317 301 1,224 326 305 304 289 1,180 300 292 300 288 705 289 293 123 - - Nutrition & Health 1,787 926 861 3,473 872 868 865 868 3,422 853 876 885 808 2,460 806 844 486 324 1,403 Performance Chemicals(1) 3,287 1,696 1,591 6,932 1,671 1,781 1,837 1,643 7,450 1,644 1,794 2,043 1,969 8,055 1,923 2,209 2,065 1,858 6,245 Performance Materials(1) 3,116 1,582 1,534 6,239 1,521 1,602 1,615 1,501 6,185 1,478 1,552 1,624 1,531 6,554 1,555 1,678 1,675 1,646 6,215 Safety & Protection 1,976 1,029 947 3,884 975 985 1,017 907 3,825 964 934 986 941 3,934 943 1,001 1,025 965 3,733 Other 2 1 1 6 1 1 3 1 5 1 2 1 1 40 1 2 1 36 160 Total Segment Sales 19,992 9,783 10,209 36,046 7,814 7,813 9,925 10,494 35,194 7,397 7,480 10,022 10,295 34,087 7,444 8,236 9,263 9,144 26,499 Elimination of Transfers (158) (77) (81) (312) (67) (78) (81) (86) (382) (72) (90) (105) (115) (406) (101) (98) (104) (103) (330) CONSOLIDATED NET SALES 19,834 9,706 10,128 35,734 7,747 7,735 9,844 10,408 34,812 7,325 7,390 9,917 10,180 33,681 7,343 8,138 9,159 9,041 26,169 (1) Prior periods reflect the reclassifications of Viton® fluoroelastomers from Performance Materials to Performance Chemicals. Note: The data above provides a historical display of selected data included in our Quarterly Earnings Release financials. SEGMENT SALES SEGMENT SALES (UNAUDITED) (dollars in millions) Non-GAAP Reconciliations
E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES Year Year Year Year Year 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11 2008 Agriculture 2,231 789 1,442 2,132 (108) (102) 861 1,481 1,669 (103) (198) 682 1,288 1,566 (222) (184) 843 1,129 1,006 Electronics & Communications 96 21 75 203 (38) 97 95 49 222 41 (99) 221 59 438 61 120 126 131 211 Industrial Biosciences 113 57 56 170 41 45 43 41 159 41 37 42 39 2 34 (26) (6) - - Nutrition & Health 190 97 93 305 87 81 61 76 270 22 64 105 79 76 54 (20) 14 28 18 Performance Chemicals(1) 438 232 206 941 228 189 268 256 1,826 210 417 613 586 2,162 496 651 571 444 619 Performance Materials(1) 958 665 293 1,264 278 367 332 287 1,073 263 223 325 262 1,031 209 251 270 301 79 Safety & Protection 353 178 175 694 213 171 172 138 562 130 92 181 159 661 131 162 184 184 601 Other (176) (84) (92) (340) (91) (107) (55) (87) (412) (80) (75) (208) (49) (55) (11) (32) 22 (34) 839 TOTAL SEGMENT PRETAX OPERATING INCOME (GAAP) 4,203 1,955 2,248 5,369 610 741 1,777 2,241 5,369 524 461 1,961 2,423 5,881 752 922 2,024 2,183 3,373 SEGMENT PRETAX IMPACT OF Year Year Year Year Year SIGNIFICANT ITEMS 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11 2008 Agriculture (47) (47) - (351) (196) (40) (80) (35) (469) (26) (128) (265) (50) (225) (100) (125) - - (5) Electronics & Communications (68) (68) - (131) (131) - - - (37) (2) (157) 122 - - - - - - (37) Industrial Biosciences (2) (2) - 1 1 - - - (3) - (3) - - (79) (1) (61) (17) - - Nutrition & Health (8) (8) - 6 6 - - - (49) (36) (13) - - (126) (4) (89) (33) - (17) Performance Chemicals (19) (19) - (74) (2) (72) - - (36) (33) (3) - - - - - - - (56) Performance Materials 362 362 - (16) (16) - - - (104) (3) (101) - - 47 47 - - - (310) Safety & Protection (31) (31) - 4 4 - - - (58) (3) (55) - - - - - - - (97) Other (2) (2) - 5 5 - - - (126) 11 - (137) - (28) (10) (18) - - (31) TOTAL SIGNIFICANT ITEMS BY SEGMENT - PRETAX 185 185 - (556) (329) (112) (80) (35) (882) (92) (460) (280) (50) (411) (68) (293) (50) - (553) Year Year Year Year Year 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11 2008 Agriculture 2,278 836 1,442 2,483 88 (62) 941 1,516 2,138 (77) (70) 947 1,338 1,791 (122) (59) 843 1,129 1,011 Electronics & Communications 164 89 75 334 93 97 95 49 259 43 58 99 59 438 61 120 126 131 248 Industrial Biosciences 115 59 56 169 40 45 43 41 162 41 40 42 39 81 35 35 11 - - Nutrition & Health 198 105 93 299 81 81 61 76 319 58 77 105 79 202 58 69 47 28 35 Performance Chemicals(1) 457 251 206 1,015 230 261 268 256 1,862 243 420 613 586 2,162 496 651 571 444 675 Performance Materials(1) 596 303 293 1,280 294 367 332 287 1,177 266 324 325 262 984 162 251 270 301 389 Safety & Protection 384 209 175 690 209 171 172 138 620 133 147 181 159 661 131 162 184 184 698 Other (174) (82) (92) (345) (96) (107) (55) (87) (286) (91) (75) (71) (49) (27) (1) (14) 22 (34) 870 TOTAL SEGMENT OPERATING EARNINGS 4,018 1,770 2,248 5,925 939 853 1,857 2,276 6,251 616 921 2,241 2,473 6,292 820 1,215 2,074 2,183 3,926 (1) Prior periods reflect the reclassifications of Viton® fluoroelastomers from Performance Materials to Performance Chemicals. Note: The data above provides a historical display of selected data included in our Quarterly Earnings Release financials. SIGNIFICANT ITEMS BY SEGMENT - PRETAX OPERATING INCOME (UNAUDITED) (dollars in millions) SEGMENT OPERATING EARNINGS OPERATING EARNINGS (UNAUDITED) (dollars in millions) SEGMENT PRETAX OPERATING INCOME (LOSS) (GAAP) INCOME FROM CONTINUING OPERATIONS (UNAUDITED) (GAAP) (dollars in millions) Non-GAAP Reconciliations
E. I. DU PONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES Year Year Year Year Year 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11 2008 SEGMENT PTOI MARGIN % (PTOI / Segment Sales) (1) Agriculture 27.9% 21.8% 32.8% 18.2% -6.0% -6.2% 23.7% 31.7% 16.0% -6.7% -13.9% 20.1% 31.6% 17.1% -17.1% -13.5% 28.1% 32.2% 15.4% Electronics & Communications 8.0% 3.4% 12.9% 8.0% -5.9% 15.2% 14.5% 8.0% 8.2% 6.6% -16.3% 27.8% 8.7% 13.8% 9.7% 14.3% 14.1% 16.2% 9.6% Industrial Biosciences 18.3% 18.0% 18.6% 13.9% 12.6% 14.8% 14.1% 14.2% 13.5% 13.7% 12.7% 14.0% 13.5% 0.3% 11.8% -8.9% -4.9% n/m n/m Nutrition & Health 10.6% 10.5% 10.8% 8.8% 10.0% 9.3% 7.1% 8.8% 7.9% 2.6% 7.3% 11.9% 9.8% 3.1% 6.7% -2.4% 2.9% 8.6% 1.3% Performance Chemicals(2) 13.3% 13.7% 12.9% 13.6% 13.6% 10.6% 14.6% 15.6% 24.5% 12.8% 23.2% 30.0% 29.8% 26.8% 25.8% 29.5% 27.7% 23.9% 9.9% Performance Materials(2) 30.7% 42.0% 19.1% 20.3% 18.3% 22.9% 20.6% 19.1% 17.3% 17.8% 14.4% 20.0% 17.1% 15.7% 13.4% 15.0% 16.1% 18.3% 1.3% Safety & Protection 17.9% 17.3% 18.5% 17.9% 21.8% 17.4% 16.9% 15.2% 14.7% 13.5% 9.9% 18.4% 16.9% 16.8% 13.9% 16.2% 18.0% 19.1% 16.1% TOTAL SEGMENT PTOI MARGIN % 21.0% 20.0% 22.0% 14.9% 7.8% 9.5% 17.9% 21.4% 15.3% 7.1% 6.2% 19.6% 23.5% 17.3% 10.1% 11.2% 21.9% 23.9% 12.7% SEGMENT OPERATING EARNINGS MARGIN % (Operating Earnings / Segment Sales) (1) Agriculture 28.4% 23.1% 32.8% 21.2% 4.9% -3.8% 25.9% 32.5% 20.5% -5.0% -4.9% 28.0% 32.8% 19.5% -9.4% -4.3% 28.1% 32.2% 15.4% Electronics & Communications 13.7% 14.4% 12.9% 13.1% 14.5% 15.2% 14.5% 8.0% 9.6% 6.9% 9.6% 12.5% 8.7% 13.8% 9.7% 14.3% 14.1% 16.2% 11.3% Industrial Biosciences 18.6% 18.6% 18.6% 13.8% 12.3% 14.8% 14.1% 14.2% 13.7% 13.7% 13.7% 14.0% 13.5% 11.5% 12.1% 11.9% 8.9% n/m n/m Nutrition & Health 11.1% 11.3% 10.8% 8.6% 9.3% 9.3% 7.1% 8.8% 9.3% 6.8% 8.8% 11.9% 9.8% 8.2% 7.2% 8.2% 9.7% 8.6% 2.5% Performance Chemicals(2) 13.9% 14.8% 12.9% 14.6% 13.8% 14.7% 14.6% 15.6% 25.0% 14.8% 23.4% 30.0% 29.8% 26.8% 25.8% 29.5% 27.7% 23.9% 10.8% Performance Materials(2) 19.1% 19.2% 19.1% 20.5% 19.3% 22.9% 20.6% 19.1% 19.0% 18.0% 20.9% 20.0% 17.1% 15.0% 10.4% 15.0% 16.1% 18.3% 6.3% Safety & Protection 19.4% 20.3% 18.5% 17.8% 21.4% 17.4% 16.9% 15.2% 16.2% 13.8% 15.7% 18.4% 16.9% 16.8% 13.9% 16.2% 18.0% 19.1% 18.7% 20.1% 18.1% 22.0% 16.4% 12.0% 10.9% 18.7% 21.7% 17.8% 8.3% 12.3% 22.4% 24.0% 18.5% 11.0% 14.8% 22.4% 23.9% 14.8% (1) Segment PTOI / Operating Earnings margin %'s for Other are not presented separately above as they are not meaningful; however, the results are included in the Total margin %'s above. (2) Prior periods reflect the reclassifications of Viton ® fluoroelastomers from Performance Materials to Performance Chemicals. TOTAL SEGMENT OPERATING EARNINGS MARGIN % RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED) Non-GAAP Reconciliations
Copyright © 2014 DuPont. All rights reserved. The DuPont Oval Logo, DuPontTM, The miracles of scienceTM, and all products denoted with ® or M are trademarks or registered trademarks of E. I. du Pont de Nemours and Company.

More Related Content

PDF
Investor Presentation – April 2015
byDupontInv
 
PDF
DuPont at Bernstein's 31st Annual Strategic Decisions Conference 2015
byDupontInv
 
PDF
Investor presentation final
byDupontInv
 
PPSX
New Approach to Pharma R&D / PPM
byKelvin Stott
 
PDF
NEOGEN MICH TECH Finish
byBrandon Hutchison
 
PPTX
Hbio slide deck sidotti 5.6.9.2014 revised 5.2.2014
byaz_hbio
 
PPTX
Merck into Emerging India
byRay Yip
 
PDF
Novartis Balanced Scorecard
byRoberta Canavesi
 
Investor Presentation – April 2015
byDupontInv
 
DuPont at Bernstein's 31st Annual Strategic Decisions Conference 2015
byDupontInv
 
Investor presentation final
byDupontInv
 
New Approach to Pharma R&D / PPM
byKelvin Stott
 
NEOGEN MICH TECH Finish
byBrandon Hutchison
 
Hbio slide deck sidotti 5.6.9.2014 revised 5.2.2014
byaz_hbio
 
Merck into Emerging India
byRay Yip
 
Novartis Balanced Scorecard
byRoberta Canavesi
 

What's hot

PDF
becton dickinson 2006AR
byfinance45
 
PPT
Biotechnology R&D and corporate strategy
byBhaswat Chakraborty
 
PDF
Guidance presentation jan 2014 final
byValeant_Pharmaceuticals
 
PDF
3b. Biotechnolgies & Genomics - Ofer Haviv
byIventus
 
PDF
Characteristics of the liquid crystals market (A Deep Dive into Merck's LC & ...
byMerck
 
PDF
EYOilGas_Unlocking the potential_FINAL_June2013
bySeelan Naicker
 
PDF
BioTime Investor Presentation 2016
byCompany Spotlight
 
PDF
IV1606_LRS
bySinead Greaney
 
PDF
wyeth Goldman Sachs Healthcare Conference
byfinance12
 
PDF
BioSingapore Whitepaper - The Next Lap Biosciences in Singapore 2025
bySimranjit Singh
 
PDF
Jpm 2015 final2
byValeant_Pharmaceuticals
 
PDF
Investors Presentation 9M|2020 Results
byAndreGro
 
PPT
Biocon Press Conference FY13 Results - April 26, 2013
byBiocon
 
PDF
Anne Waddell, Vice President, Public Affairs, BioAmber Inc.
bySustainable Prosperity
 
PPTX
Strategic management - An Outlook on Growth strategy
byNeha Kalal
 
PPTX
Sanofi mongodb-world-20140625-final
byMongoDB
 
PDF
Novartis cr-performance-report-2015
byEthos Media S.A.
 
PDF
Investor Handout Meet Management 2013 New York June 2013
byBayer
 
becton dickinson 2006AR
byfinance45
 
Biotechnology R&D and corporate strategy
byBhaswat Chakraborty
 
Guidance presentation jan 2014 final
byValeant_Pharmaceuticals
 
3b. Biotechnolgies & Genomics - Ofer Haviv
byIventus
 
Characteristics of the liquid crystals market (A Deep Dive into Merck's LC & ...
byMerck
 
EYOilGas_Unlocking the potential_FINAL_June2013
bySeelan Naicker
 
BioTime Investor Presentation 2016
byCompany Spotlight
 
IV1606_LRS
bySinead Greaney
 
wyeth Goldman Sachs Healthcare Conference
byfinance12
 
BioSingapore Whitepaper - The Next Lap Biosciences in Singapore 2025
bySimranjit Singh
 
Jpm 2015 final2
byValeant_Pharmaceuticals
 
Investors Presentation 9M|2020 Results
byAndreGro
 
Biocon Press Conference FY13 Results - April 26, 2013
byBiocon
 
Anne Waddell, Vice President, Public Affairs, BioAmber Inc.
bySustainable Prosperity
 
Strategic management - An Outlook on Growth strategy
byNeha Kalal
 
Sanofi mongodb-world-20140625-final
byMongoDB
 
Novartis cr-performance-report-2015
byEthos Media S.A.
 
Investor Handout Meet Management 2013 New York June 2013
byBayer
 

Viewers also liked

PDF
itw Annual Investor Day PartI
byfinance16
 
PDF
2016 Make Your Mark at ITW
byJulia Scales
 
PDF
George W. Buckley Chairman, President and Chief Executive Officer
byfinance10
 
PPT
Energy Management by Food&Beverage Industry
byAvanceon
 
PDF
DuPont Thailand Innovation Center Overview
byDuPont
 
PDF
Huber+Suhner Company presentation 2016
byFrank Rothe
 
PPT
Distribution strategy
bySlides Presentation
 
PPT
3M Leading Through Innovation
byRoberto Andres Castillo Zavala
 
PPTX
3M
byRobin Bansal
 
PDF
Distribution strategy
byrajwindernijjar1
 
PPTX
Innovation at 3M case analysis
byTony Sebastian
 
itw Annual Investor Day PartI
byfinance16
 
2016 Make Your Mark at ITW
byJulia Scales
 
George W. Buckley Chairman, President and Chief Executive Officer
byfinance10
 
Energy Management by Food&Beverage Industry
byAvanceon
 
DuPont Thailand Innovation Center Overview
byDuPont
 
Huber+Suhner Company presentation 2016
byFrank Rothe
 
Distribution strategy
bySlides Presentation
 
3M Leading Through Innovation
byRoberto Andres Castillo Zavala
 
3M
byRobin Bansal
 
Distribution strategy
byrajwindernijjar1
 
Innovation at 3M case analysis
byTony Sebastian
 

Similar to DuPont Presents at Jefferies 10th Annual Global Industrials Conference

PDF
DuPont Presents at Citi 2014 Basic Materials Conference
byDupontInv
 
PDF
Dupont Slides Sanford Bernstein final 5 27-14
byDupontInv
 
PDF
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
byDupontInv
 
PDF
Credit Suisse Presentation, September 18 2014
byDupontInv
 
PDF
2 q14 slides final
byDupontInv
 
PDF
du pont 2007 annual report
byfinance9
 
PDF
Du pont 2q15 slides final
byDupontInv
 
PDF
Du pont 3q15 Slides Final
byDupontInv
 
DOCX
DuPont Company
byshundushmumtaz
 
PDF
Du pont 4q15 slides final
byDupontInv
 
PDF
Du pont 3q14 slides final
byDupontInv
 
PDF
Du pont 4q14 slides final
byDupontInv
 
PDF
Du pont 4q14 slides final
byDupontInv
 
PDF
DuPont Fact Sheet
byDupontInv
 
PDF
Du pont 1q15 slides final
byDupontInv
 
DOCX
Business Model and Strategic Plan Part I Conceptualizing a NewP.docx
byhumphrieskalyn
 
PDF
Strategy Summit: Rob Kirschbaum - DSM’s journey from mining to sciences
byEngage // Innovate
 
PDF
RA Revisited 270911 DSM Jaco Fok
byRicoh Academy NL
 
PDF
dupont va chiến lược của họ trong thị trường
byNguynTm817508
 
PDF
du pont Earnings Release2008 1st
byfinance9
 
DuPont Presents at Citi 2014 Basic Materials Conference
byDupontInv
 
Dupont Slides Sanford Bernstein final 5 27-14
byDupontInv
 
DuPont at J.P. Morgan Aviation, Transportation and Industrials Conference
byDupontInv
 
Credit Suisse Presentation, September 18 2014
byDupontInv
 
2 q14 slides final
byDupontInv
 
du pont 2007 annual report
byfinance9
 
Du pont 2q15 slides final
byDupontInv
 
Du pont 3q15 Slides Final
byDupontInv
 
DuPont Company
byshundushmumtaz
 
Du pont 4q15 slides final
byDupontInv
 
Du pont 3q14 slides final
byDupontInv
 
Du pont 4q14 slides final
byDupontInv
 
Du pont 4q14 slides final
byDupontInv
 
DuPont Fact Sheet
byDupontInv
 
Du pont 1q15 slides final
byDupontInv
 
Business Model and Strategic Plan Part I Conceptualizing a NewP.docx
byhumphrieskalyn
 
Strategy Summit: Rob Kirschbaum - DSM’s journey from mining to sciences
byEngage // Innovate
 
RA Revisited 270911 DSM Jaco Fok
byRicoh Academy NL
 
dupont va chiến lược của họ trong thị trường
byNguynTm817508
 
du pont Earnings Release2008 1st
byfinance9
 

More from DupontInv

PDF
Du pont 1q17 slides final
byDupontInv
 
PDF
Du pont & fmc transactions presentation
byDupontInv
 
PDF
Project liberty investor relations presentation final
byDupontInv
 
PDF
DuPont at Bank of America Merrill Lynch Global Agriculture and Chemicals Conf...
byDupontInv
 
PDF
Du pont 4q16_slides_final
byDupontInv
 
PDF
Du pont 3q16_slides_final
byDupontInv
 
PDF
Du pont 2q16_slides_final
byDupontInv
 
PDF
Dupont Q1 2016 Earnings Presentation
byDupontInv
 
PDF
2016 baml conference final
byDupontInv
 
PDF
DuPont and Dow Merger Presentation 2015
byDupontInv
 
PDF
Baml conference 2015 final
byDupontInv
 
PDF
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
byDupontInv
 
PDF
Morgan Stanley Investor Presentation
byDupontInv
 
PDF
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
byDupontInv
 
Du pont 1q17 slides final
byDupontInv
 
Du pont & fmc transactions presentation
byDupontInv
 
Project liberty investor relations presentation final
byDupontInv
 
DuPont at Bank of America Merrill Lynch Global Agriculture and Chemicals Conf...
byDupontInv
 
Du pont 4q16_slides_final
byDupontInv
 
Du pont 3q16_slides_final
byDupontInv
 
Du pont 2q16_slides_final
byDupontInv
 
Dupont Q1 2016 Earnings Presentation
byDupontInv
 
2016 baml conference final
byDupontInv
 
DuPont and Dow Merger Presentation 2015
byDupontInv
 
Baml conference 2015 final
byDupontInv
 
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
byDupontInv
 
Morgan Stanley Investor Presentation
byDupontInv
 
DuPont Presents at Morgan Stanley Global Chemicals and Agriculture Conference
byDupontInv
 

Recently uploaded

PDF
Sysco Fiscal Q2 2026 Earnings Results Presentation
bySysco_Investors
 
PDF
Collective Mining | Corporate Presentation - January 2026
byCollective Mining
 
PPTX
Alaska Silver Corporate Presentation January 23 2026.pptx
byvanessa47939
 
PDF
[ls머트리얼즈]LS Materials 417200 Algorithm Investment Report
by알고리즘 기업분석 컨설팅-알기컨,algikeon
 
PDF
Collective Mining | Corporate Presentation - January 2026
byCollective Mining
 
PDF
cyberagent___For New Investors_JP_251114
byCyberAgent, Inc.
 
PDF
How to Navigate the Process of Buying Snapchat Accounts in New York.pdf
byBusiness
 
Sysco Fiscal Q2 2026 Earnings Results Presentation
bySysco_Investors
 
Collective Mining | Corporate Presentation - January 2026
byCollective Mining
 
Alaska Silver Corporate Presentation January 23 2026.pptx
byvanessa47939
 
[ls머트리얼즈]LS Materials 417200 Algorithm Investment Report
by알고리즘 기업분석 컨설팅-알기컨,algikeon
 
Collective Mining | Corporate Presentation - January 2026
byCollective Mining
 
cyberagent___For New Investors_JP_251114
byCyberAgent, Inc.
 
How to Navigate the Process of Buying Snapchat Accounts in New York.pdf
byBusiness
 

DuPont Presents at Jefferies 10th Annual Global Industrials Conference

  • 1.
    DuPont: Building HigherGrowth, Higher Value Through Science Douglas Muzyka, Ph.D. Senior Vice President; Chief Science & Technology Officer
  • 2.
    2 2 Regulation G The attachedcharts include company information that does not conform to generally accepted accounting principles (GAAP). Management believes that an analysis of this data is meaningful to investors because it provides insight with respect to ongoing operating results of the company and allows investors to better evaluate the financial results of the company. These measures should not be viewed as an alternative to GAAP measures of performance. Furthermore, these measures may not be consistent with similar measures provided by other companies. This data should be read in conjunction with previously published company reports on Forms 10-K, 10-Q, and 8-K. These reports, along with reconciliations of non-GAAP measures to GAAP are available on the Investor Center of www.dupont.com under Key Financials & Filings. Forward Looking Statements During the course of this presentation we may make forward-looking statements or provide forward-looking information. All statements that address expectations or projections about the future are forward-looking statements. Some of these statements include words such as “plans,” “expects,” “will,” “anticipates,” "believes," “intends,” and “estimates.” Although they reflect our current expectations, these statements are not guarantees of future performance, but involve a number of risks, uncertainties, and assumptions. Some of which include: fluctuations in energy and raw material prices; failure to develop and market new products and optimally manage product life cycles; global economic and capital markets conditions; litigation and environmental matters; changes in laws and regulations or political conditions; business or supply disruptions; ability to protect and enforce the company’s intellectual property rights; successful integration of acquired business and separation of underperforming or non-strategic assets; and successful completion of the proposed spinoff of the Performance Chemicals segment including ability to fully realize the expected benefits of the proposed spinoff. The company does not undertake to update any forward-looking statements as a result of future developments or new information. Developing Markets Total developing markets is comprised of Developing Asia, Developing Europe, Middle East & Africa, and Latin America. A detailed list of all developing countries is available on the Earnings News Release link on the Investor Center website at www.dupont.com.
  • 3.
    DuPont is aScience Company We work collaboratively to find sustainable, innovative, market- driven solutions to solve some of the world’s biggest challenges, making lives better, safer, and healthier for people everywhere. © National Geographic image Our Purpose 3
  • 4.
    Science is theGrowth Engine for the Company *2013 revenue from products introduced in the last four years $ 5.8B* new product revenue $ 0.4B* new product revenue $ 3.9B* new product revenue Ag & Nutrition Bio-Based Industrials Advanced Materials • Seeds • Traits • Crop Protection • Specialty Food Ingredients • Enzymes • Biomaterials • Biofuels • Biochemicals • Electronic Materials • Protective Materials • Alternative Energy • Advanced Polymers • Advanced Processes 4
  • 5.
    AG & NUTRITION BIO-BASED INDUSTRIALS ADVANCED MATERIALS Three StrategicPriorities Drive the Value of DuPont… Extend leadership across high-value, science-driven segments of the Ag and food value chain Develop world-leading industrial biotech capabilities to create new businesses Grow leading position in differentiated high- value materials 5 Higher Growth, Higher Value Company Through Three World-Leading Positions
  • 6.
    • Rigorous pipeline management •Disciplined project execution • Increasing return on R&D • Driving penetration in fast-growing, developing markets • Delivering ongoing productivity • Optimizing resource allocation • Returning cash to shareholders …Together with Three Key Operational Priorities INNOVATION GLOBAL REACH EXECUTION 6
  • 7.
  • 8.
    Disciplined Project ManagementEnsures Alignment Between Science and Integrated Business Innovation Processes Stage 0 Governance & Project Execution Innovation Portfolio Management Ideas & Opportunity Choices Insights Brand Technology Marketing Launch Management 8
  • 9.
    Increasing our Returnon R&D Key Aspects of Measurement Process • Segmentation of R&D spend into 4 categories • Strict financial rigor behind R&D programs • Calculation of projected returns on top R&D programs • Metrics package & dashboards to assess progress versus commitments R&D Spend Distribution Discovery and Major Growth Sustain and Incremental Growth 9 Disciplined and Rigorous Process to Measure and Improve Return on R&D
  • 10.
    10 Exceeded $1 Billion Revenuein 2013 Optimum® AQUAmax® Hybrids Agriculture-Discovery & Major Growth Rynaxypyr® Insecticide 10 Million Acres Expected in 2014 2008-2013: 12% Sales CAGR, Operating Margins +600bps* *Non GAAP Number, See Appendix
  • 11.
    11 Solamet® Frontside Silver PastesAdvancing Solar Cell Efficiency DuPont™ OLED Technology Electronics & Communications-Discovery & Major Growth Solamet® Two License Agreements Industry Leading Market Positions, Innovation Fueling Earnings Growth
  • 12.
    12 Cellulosic Ethanol Plant IndustrialBiosciences-Discovery & Major Growth Cold Water Enzymes 1st Half 2014 Operating Earnings Increased 37%, Operating Margins Increased 440bps* Innovation of the Year** Start up expected late 2014 Nevada, Iowa **2014 Sustainable Bio Award for Bio-Based Product Innovation of the Year*Non GAAP Number, See Appendix
  • 13.
    13 Products for children,adults and sports enthusiasts Improved Health Nutrition & Health-Discovery & Major Growth Probiotics Regulatory Achievements & New Capacity 1st Half 2014 Operating Earnings Increased 45%*, Operating Margins Increased 320bps* HOWARU® Protect probiotics *Non GAAP Number, See Appendix
  • 14.
    DuPont™ Opteon® YFRefrigerant • Collaborative approach to development • A near drop-in solution to enable regulatory compliance • Expect 2014 sales of $100 million Performance Chemicals- Discovery & Major Growth Science Meeting Market Needs for more Sustainable Solutions 14
  • 15.
    15 Five Patents Granted, TwoIn Progress Surlyn® Ionomer Performance Materials-Sustained and Incremental Growth Zytel® RS Renewable Polymers New Golf Ball Line 2014 Operating Margins of 19%*, Above Long Term Goal of 16-18% *Non GAAP Number, See Appendix
  • 16.
    16 Tyvek® ThermaWrap™ DuPont™ Kevlar® Safety& Protection -Sustained and Incremental Growth New Launches 50 Years of Innovation 1st Half 2014 Operating Earnings increased 24%*, Operating Margins increased 330bps* *Non GAAP Number, See Appendix
  • 17.
    Putting Science toWork: Where we are Going 17
  • 18.
    …COMPELLING MARKET INSIGHTSTO SOLVE WORLD SCALE CHALLENGES WORLD CLASS INTEGRATED SCIENCE COUPLED WITH… Translating Science into Solutions Materials Science Chemistry Biological Sciences Engineering Integration of emerging biological sciences FOOD ENERGY PROTECTION Materials ScienceChemistry Biological SciencesEngineering 18 DuPont is on the Forefront of Another Wave of Innovation
  • 19.
    19 7% 12%Sales CAGROperating EPS CAGR* Ushering in the next era of innovation OPERATIONAL PRIORITIES Innovation Global Reach Execution STRATEGIC PRIORITIES Extended Ag & Nutrition Leadership Build Bio-based Businesses Strengthen Advanced Materials Long Term Growth Targets 19 *Non GAAP Number
  • 20.
    E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES NON-GAAP RECONCILIATIONS (UNAUDITED) JUNE 30, 2014 Note : Operating earnings are defined as earnings from continuing operations (GAAP) excluding “significant items” and “non-operating pension and other post-employment benefit (OPEB) costs”. Management believes that an analysis of operating earnings, a "non-GAAP" measure, is meaningful to investors because it provides insight with respect to ongoing operating results of the company. Such measurements are not recognized in accordance with generally accepted accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance. Non-GAAP Reconciliations
  • 21.
    E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES Year Year Year Year Year 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11 2008 Agriculture 8,009 3,615 4,394 11,739 1,806 1,633 3,631 4,669 10,426 1,535 1,423 3,388 4,080 9,166 1,297 1,368 2,997 3,504 6,549 Electronics & Communications 1,197 617 580 2,549 642 638 653 616 2,701 622 607 795 677 3,173 630 841 891 811 2,194 Industrial Biosciences 618 317 301 1,224 326 305 304 289 1,180 300 292 300 288 705 289 293 123 - - Nutrition & Health 1,787 926 861 3,473 872 868 865 868 3,422 853 876 885 808 2,460 806 844 486 324 1,403 Performance Chemicals(1) 3,287 1,696 1,591 6,932 1,671 1,781 1,837 1,643 7,450 1,644 1,794 2,043 1,969 8,055 1,923 2,209 2,065 1,858 6,245 Performance Materials(1) 3,116 1,582 1,534 6,239 1,521 1,602 1,615 1,501 6,185 1,478 1,552 1,624 1,531 6,554 1,555 1,678 1,675 1,646 6,215 Safety & Protection 1,976 1,029 947 3,884 975 985 1,017 907 3,825 964 934 986 941 3,934 943 1,001 1,025 965 3,733 Other 2 1 1 6 1 1 3 1 5 1 2 1 1 40 1 2 1 36 160 Total Segment Sales 19,992 9,783 10,209 36,046 7,814 7,813 9,925 10,494 35,194 7,397 7,480 10,022 10,295 34,087 7,444 8,236 9,263 9,144 26,499 Elimination of Transfers (158) (77) (81) (312) (67) (78) (81) (86) (382) (72) (90) (105) (115) (406) (101) (98) (104) (103) (330) CONSOLIDATED NET SALES 19,834 9,706 10,128 35,734 7,747 7,735 9,844 10,408 34,812 7,325 7,390 9,917 10,180 33,681 7,343 8,138 9,159 9,041 26,169 (1) Prior periods reflect the reclassifications of Viton® fluoroelastomers from Performance Materials to Performance Chemicals. Note: The data above provides a historical display of selected data included in our Quarterly Earnings Release financials. SEGMENT SALES SEGMENT SALES (UNAUDITED) (dollars in millions) Non-GAAP Reconciliations
  • 22.
    E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES Year Year Year Year Year 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11 2008 Agriculture 2,231 789 1,442 2,132 (108) (102) 861 1,481 1,669 (103) (198) 682 1,288 1,566 (222) (184) 843 1,129 1,006 Electronics & Communications 96 21 75 203 (38) 97 95 49 222 41 (99) 221 59 438 61 120 126 131 211 Industrial Biosciences 113 57 56 170 41 45 43 41 159 41 37 42 39 2 34 (26) (6) - - Nutrition & Health 190 97 93 305 87 81 61 76 270 22 64 105 79 76 54 (20) 14 28 18 Performance Chemicals(1) 438 232 206 941 228 189 268 256 1,826 210 417 613 586 2,162 496 651 571 444 619 Performance Materials(1) 958 665 293 1,264 278 367 332 287 1,073 263 223 325 262 1,031 209 251 270 301 79 Safety & Protection 353 178 175 694 213 171 172 138 562 130 92 181 159 661 131 162 184 184 601 Other (176) (84) (92) (340) (91) (107) (55) (87) (412) (80) (75) (208) (49) (55) (11) (32) 22 (34) 839 TOTAL SEGMENT PRETAX OPERATING INCOME (GAAP) 4,203 1,955 2,248 5,369 610 741 1,777 2,241 5,369 524 461 1,961 2,423 5,881 752 922 2,024 2,183 3,373 SEGMENT PRETAX IMPACT OF Year Year Year Year Year SIGNIFICANT ITEMS 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11 2008 Agriculture (47) (47) - (351) (196) (40) (80) (35) (469) (26) (128) (265) (50) (225) (100) (125) - - (5) Electronics & Communications (68) (68) - (131) (131) - - - (37) (2) (157) 122 - - - - - - (37) Industrial Biosciences (2) (2) - 1 1 - - - (3) - (3) - - (79) (1) (61) (17) - - Nutrition & Health (8) (8) - 6 6 - - - (49) (36) (13) - - (126) (4) (89) (33) - (17) Performance Chemicals (19) (19) - (74) (2) (72) - - (36) (33) (3) - - - - - - - (56) Performance Materials 362 362 - (16) (16) - - - (104) (3) (101) - - 47 47 - - - (310) Safety & Protection (31) (31) - 4 4 - - - (58) (3) (55) - - - - - - - (97) Other (2) (2) - 5 5 - - - (126) 11 - (137) - (28) (10) (18) - - (31) TOTAL SIGNIFICANT ITEMS BY SEGMENT - PRETAX 185 185 - (556) (329) (112) (80) (35) (882) (92) (460) (280) (50) (411) (68) (293) (50) - (553) Year Year Year Year Year 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11 2008 Agriculture 2,278 836 1,442 2,483 88 (62) 941 1,516 2,138 (77) (70) 947 1,338 1,791 (122) (59) 843 1,129 1,011 Electronics & Communications 164 89 75 334 93 97 95 49 259 43 58 99 59 438 61 120 126 131 248 Industrial Biosciences 115 59 56 169 40 45 43 41 162 41 40 42 39 81 35 35 11 - - Nutrition & Health 198 105 93 299 81 81 61 76 319 58 77 105 79 202 58 69 47 28 35 Performance Chemicals(1) 457 251 206 1,015 230 261 268 256 1,862 243 420 613 586 2,162 496 651 571 444 675 Performance Materials(1) 596 303 293 1,280 294 367 332 287 1,177 266 324 325 262 984 162 251 270 301 389 Safety & Protection 384 209 175 690 209 171 172 138 620 133 147 181 159 661 131 162 184 184 698 Other (174) (82) (92) (345) (96) (107) (55) (87) (286) (91) (75) (71) (49) (27) (1) (14) 22 (34) 870 TOTAL SEGMENT OPERATING EARNINGS 4,018 1,770 2,248 5,925 939 853 1,857 2,276 6,251 616 921 2,241 2,473 6,292 820 1,215 2,074 2,183 3,926 (1) Prior periods reflect the reclassifications of Viton® fluoroelastomers from Performance Materials to Performance Chemicals. Note: The data above provides a historical display of selected data included in our Quarterly Earnings Release financials. SIGNIFICANT ITEMS BY SEGMENT - PRETAX OPERATING INCOME (UNAUDITED) (dollars in millions) SEGMENT OPERATING EARNINGS OPERATING EARNINGS (UNAUDITED) (dollars in millions) SEGMENT PRETAX OPERATING INCOME (LOSS) (GAAP) INCOME FROM CONTINUING OPERATIONS (UNAUDITED) (GAAP) (dollars in millions) Non-GAAP Reconciliations
  • 23.
    E. I. DUPONT DE NEMOURS AND COMPANY AND CONSOLIDATED SUBSIDIARIES Year Year Year Year Year 2014 2Q14 1Q14 2013 4Q13 3Q13 2Q13 1Q13 2012 4Q12 3Q12 2Q12 1Q12 2011 4Q11 3Q11 2Q11 1Q11 2008 SEGMENT PTOI MARGIN % (PTOI / Segment Sales) (1) Agriculture 27.9% 21.8% 32.8% 18.2% -6.0% -6.2% 23.7% 31.7% 16.0% -6.7% -13.9% 20.1% 31.6% 17.1% -17.1% -13.5% 28.1% 32.2% 15.4% Electronics & Communications 8.0% 3.4% 12.9% 8.0% -5.9% 15.2% 14.5% 8.0% 8.2% 6.6% -16.3% 27.8% 8.7% 13.8% 9.7% 14.3% 14.1% 16.2% 9.6% Industrial Biosciences 18.3% 18.0% 18.6% 13.9% 12.6% 14.8% 14.1% 14.2% 13.5% 13.7% 12.7% 14.0% 13.5% 0.3% 11.8% -8.9% -4.9% n/m n/m Nutrition & Health 10.6% 10.5% 10.8% 8.8% 10.0% 9.3% 7.1% 8.8% 7.9% 2.6% 7.3% 11.9% 9.8% 3.1% 6.7% -2.4% 2.9% 8.6% 1.3% Performance Chemicals(2) 13.3% 13.7% 12.9% 13.6% 13.6% 10.6% 14.6% 15.6% 24.5% 12.8% 23.2% 30.0% 29.8% 26.8% 25.8% 29.5% 27.7% 23.9% 9.9% Performance Materials(2) 30.7% 42.0% 19.1% 20.3% 18.3% 22.9% 20.6% 19.1% 17.3% 17.8% 14.4% 20.0% 17.1% 15.7% 13.4% 15.0% 16.1% 18.3% 1.3% Safety & Protection 17.9% 17.3% 18.5% 17.9% 21.8% 17.4% 16.9% 15.2% 14.7% 13.5% 9.9% 18.4% 16.9% 16.8% 13.9% 16.2% 18.0% 19.1% 16.1% TOTAL SEGMENT PTOI MARGIN % 21.0% 20.0% 22.0% 14.9% 7.8% 9.5% 17.9% 21.4% 15.3% 7.1% 6.2% 19.6% 23.5% 17.3% 10.1% 11.2% 21.9% 23.9% 12.7% SEGMENT OPERATING EARNINGS MARGIN % (Operating Earnings / Segment Sales) (1) Agriculture 28.4% 23.1% 32.8% 21.2% 4.9% -3.8% 25.9% 32.5% 20.5% -5.0% -4.9% 28.0% 32.8% 19.5% -9.4% -4.3% 28.1% 32.2% 15.4% Electronics & Communications 13.7% 14.4% 12.9% 13.1% 14.5% 15.2% 14.5% 8.0% 9.6% 6.9% 9.6% 12.5% 8.7% 13.8% 9.7% 14.3% 14.1% 16.2% 11.3% Industrial Biosciences 18.6% 18.6% 18.6% 13.8% 12.3% 14.8% 14.1% 14.2% 13.7% 13.7% 13.7% 14.0% 13.5% 11.5% 12.1% 11.9% 8.9% n/m n/m Nutrition & Health 11.1% 11.3% 10.8% 8.6% 9.3% 9.3% 7.1% 8.8% 9.3% 6.8% 8.8% 11.9% 9.8% 8.2% 7.2% 8.2% 9.7% 8.6% 2.5% Performance Chemicals(2) 13.9% 14.8% 12.9% 14.6% 13.8% 14.7% 14.6% 15.6% 25.0% 14.8% 23.4% 30.0% 29.8% 26.8% 25.8% 29.5% 27.7% 23.9% 10.8% Performance Materials(2) 19.1% 19.2% 19.1% 20.5% 19.3% 22.9% 20.6% 19.1% 19.0% 18.0% 20.9% 20.0% 17.1% 15.0% 10.4% 15.0% 16.1% 18.3% 6.3% Safety & Protection 19.4% 20.3% 18.5% 17.8% 21.4% 17.4% 16.9% 15.2% 16.2% 13.8% 15.7% 18.4% 16.9% 16.8% 13.9% 16.2% 18.0% 19.1% 18.7% 20.1% 18.1% 22.0% 16.4% 12.0% 10.9% 18.7% 21.7% 17.8% 8.3% 12.3% 22.4% 24.0% 18.5% 11.0% 14.8% 22.4% 23.9% 14.8% (1) Segment PTOI / Operating Earnings margin %'s for Other are not presented separately above as they are not meaningful; however, the results are included in the Total margin %'s above. (2) Prior periods reflect the reclassifications of Viton ® fluoroelastomers from Performance Materials to Performance Chemicals. TOTAL SEGMENT OPERATING EARNINGS MARGIN % RECONCILIATION OF NON-GAAP MEASURES (UNAUDITED) Non-GAAP Reconciliations
  • 24.
    Copyright © 2014DuPont. All rights reserved. The DuPont Oval Logo, DuPontTM, The miracles of scienceTM, and all products denoted with ® or M are trademarks or registered trademarks of E. I. du Pont de Nemours and Company.